BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 12168875)

  • 1. Amifostine promotes hemopoietic progenitor cell mobilization in patients with myelodysplastic syndrome.
    Arboscello E; Botta M; Lerza R; Bogliolo G; Clavio M; Miglino M; Mencoboni M; Pannacciulli I
    Anticancer Res; 2002; 22(3):1819-24. PubMed ID: 12168875
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of anemia in low-risk myelodysplastic syndromes with amifostine. In vitro testing of response.
    Viniou N; Terpos E; Galanopoulos A; Kritikou-Griva E; Akel S; Michalis E; Apostolidou E; Georgiadou D; Kouraklis A; Parharidou A; Kokkini G; Symeonidis A; Anagnostopoulos NI; Christakis JI; Tasiopoulou A; Loukopoulos D; Yataganas X
    Ann Hematol; 2002 Apr; 81(4):182-6. PubMed ID: 11976818
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Amifostine exerts anti-angiogenic activity and suppresses vascular endothelial growth factor secreted by hemopoietic stem/progenitor cells.
    Akel SM; Atoum MF; Saleh SA; Awadallah SM
    Saudi Med J; 2005 Oct; 26(10):1523-8. PubMed ID: 16228049
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of retinoic acid and amifostine on in vitro growth of normal hemopoietic progenitor cells.
    Arboscello E; Botta M; Romero D; Schenone E; Mencoboni M; Bogliolo G; Pannacciulli I
    Anticancer Res; 2001; 21(2A):1139-43. PubMed ID: 11396153
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changes in hemopoietic precursors after treatment of low-risk myelodysplasia with amifostine.
    Ribeiro E; Lima CS; Metze K; Souza CA; Lorand-Metze I
    In Vivo; 2003; 17(2):181-4. PubMed ID: 12792983
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pegylated granulocyte colony-stimulating factor mobilizes CD34+ cells with different stem and progenitor subsets and distinct functional properties in comparison with unconjugated granulocyte colony-stimulating factor.
    Bruns I; Steidl U; Fischer JC; Czibere A; Kobbe G; Raschke S; Singh R; Fenk R; Rosskopf M; Pechtel S; von Haeseler A; Wernet P; Tenen DG; Haas R; Kronenwett R
    Haematologica; 2008 Mar; 93(3):347-55. PubMed ID: 18268278
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro and in vivo effects of recombinant interferon gamma on the growth of hematopoietic progenitor cells from patients with myelodysplastic syndrome.
    Rosti V; Carlo-Stella C; Pedrazzoli P; Cazzola M
    Haematologica; 1989; 74(5):435-40. PubMed ID: 2511112
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Amifostine in the treatment of low-risk myelodysplastic syndromes.
    Grossi A; Fabbri A; Santini V; Leoni F; Nozzoli C; Longo G; Pagliai G; Ciolli S; Rossi Ferrini P
    Haematologica; 2000 Apr; 85(4):367-71. PubMed ID: 10756361
    [TBL] [Abstract][Full Text] [Related]  

  • 9. GATA-1 transcription factor is up-regulated in bone marrow hematopoietic progenitor CD34(+) and erythroid CD71(+) cells in myelodysplastic syndromes.
    Maratheftis CI; Bolaraki PE; Voulgarelis M
    Am J Hematol; 2007 Oct; 82(10):887-92. PubMed ID: 17570514
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Amifostine plus erythropoietin in a patient with low-risk myelodysplastic syndrome.
    Musch E; Malek M; Chrissafidou A
    Ann Hematol; 2003 Apr; 82(4):244-6. PubMed ID: 12707729
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preliminary results of amifostine administration in combination with recombinant human erythropoietin in patients with myelodysplastic syndromes.
    Tsiara SN; Kapsali HD; Panteli K; Christou L; Bourantas KL
    J Exp Clin Cancer Res; 2001 Mar; 20(1):35-8. PubMed ID: 11370827
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of patients with myelodysplastic syndrome with amifostine.
    Galanopoulos A; Kritikou-Griva E; Gligori J; Michalis E; Grigoraki V; Marinakis T; Kakkas J; Tasiopoulou A; Anagnostopoulos NI
    Leuk Res; 2001 Aug; 25(8):665-71. PubMed ID: 11397471
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The impact of progenitor enrichment, serum, and cytokines on the ex vivo expansion of mobilized peripheral blood stem cells: a controlled trial.
    Balducci E; Azzarello G; Valenti MT; Capuzzo GM; Pappagallo GL; Pilotti I; Ausoni S; Bari M; Rosetti F; Sartori D; Ciappa A; Porcellini A; Vinante O
    Stem Cells; 2003; 21(1):33-40. PubMed ID: 12529549
    [TBL] [Abstract][Full Text] [Related]  

  • 14. G-CSF during large field radiotherapy reduces bone marrow recovery capacity.
    Pape H; Orth K; Heese A; Heyll A; Kobbe G; Schmitt G; Niederbichler AD; Peiper M; Schwarz A; Boelke E
    Eur J Med Res; 2006 Aug; 11(8):322-8. PubMed ID: 17052967
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mobilization of hematopoietic progenitors in low-grade myelodysplastic syndromes.
    Mijovic A; Delforge M; Sekhavat M; Czepulkowski B; Mufti GJ
    Haematologica; 2006 Apr; 91(4):572-3. PubMed ID: 16533722
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The CXCR4 agonist peptide, CTCE-0021, rapidly mobilizes polymorphonuclear neutrophils and hematopoietic progenitor cells into peripheral blood and synergizes with granulocyte colony-stimulating factor.
    Pelus LM; Bian H; Fukuda S; Wong D; Merzouk A; Salari H
    Exp Hematol; 2005 Mar; 33(3):295-307. PubMed ID: 15730853
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vivo activity of the cleaved form of soluble urokinase receptor: a new hematopoietic stem/progenitor cell mobilizer.
    Selleri C; Montuori N; Ricci P; Visconte V; Baiano A; Carriero MV; Rotoli B; Rossi G; Ragno P
    Cancer Res; 2006 Nov; 66(22):10885-90. PubMed ID: 17108125
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human hematopoietic stem/progenitor-enriched CD34(+) cells are mobilized into peripheral blood during stress related to ischemic stroke or acute myocardial infarction.
    Paczkowska E; Larysz B; Rzeuski R; Karbicka A; Jałowiński R; Kornacewicz-Jach Z; Ratajczak MZ; Machaliński B
    Eur J Haematol; 2005 Dec; 75(6):461-7. PubMed ID: 16313257
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel anti-inflammatory function of human galectin-1: inhibition of hematopoietic progenitor cell mobilization.
    Kiss J; Kunstár A; Fajka-Boja R; Dudics V; Tóvári J; Légrádi A; Monostori E; Uher F
    Exp Hematol; 2007 Feb; 35(2):305-13. PubMed ID: 17258079
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Growth factors mobilize CXCR4 low/negative primitive hematopoietic stem/progenitor cells from the bone marrow of nonhuman primates.
    Mahmud N; Patel H; Hoffman R
    Biol Blood Marrow Transplant; 2004 Oct; 10(10):681-90. PubMed ID: 15389434
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.